Arnon Karni - Search Results

Year	Number of Results
2002	1
2003	2
2004	2
2005	2
2006	2
2008	2
2009	2
2010	4
2011	6
2012	3
2013	3
2014	5
2015	4
2016	6
2017	5
2018	2
2019	5
2020	5
2021	1

1

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS; ORATORIO Clinical Investigators. Montalban X, et al. N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21. N Engl J Med. 2017. PMID: 28002688 Free article. Clinical Trial.

2

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.

3

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators. Coles AJ, et al. Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1. Lancet. 2012. PMID: 23122650 Clinical Trial.

4

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.

Giovannoni G, Cohen JA, Coles AJ, Hartung HP, Havrdova E, Selmaj KW, Margolin DH, Lake SL, Kaup SM, Panzara MA, Compston DA; CARE-MS II Investigators. Giovannoni G, et al. Neurology. 2016 Nov 8;87(19):1985-1992. doi: 10.1212/WNL.0000000000003319. Epub 2016 Oct 12. Neurology. 2016. PMID: 27733571 Free PMC article. Clinical Trial.

5

Erdheim-Chester disease presenting with chorea and mimicking IgG4-related disorder.

Miron G, Karni A, Faust-Soher A, Giladi N, Alroy H, Gadoth A. Miron G, et al. Among authors: karni a. Neurol Clin Pract. 2019 Dec;9(6):524-526. doi: 10.1212/CPJ.0000000000000617. Neurol Clin Pract. 2019. PMID: 32042499 Free PMC article. No abstract available.

6

Early post-marketing experience with edaravone in an unselected group of patients with ALS.

Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Abraham A, et al. Among authors: karni a. Amyotroph Lateral Scler Frontotemporal Degener. 2019 May;20(3-4):260-263. doi: 10.1080/21678421.2019.1572191. Epub 2019 Feb 20. Amyotroph Lateral Scler Frontotemporal Degener. 2019. PMID: 30784320

7

Reduced levels of Coco in sera of multiple sclerosis patients: A potential role in neuro-regeneration failure.

Mausner-Fainberg K, Penn M, Golan M, Benhamou M, Wilf-Yarkoni A, Gertel S, Karni A. Mausner-Fainberg K, et al. Among authors: karni a. J Neuroimmunol. 2019 Feb 15;327:36-40. doi: 10.1016/j.jneuroim.2019.01.009. Epub 2019 Jan 17. J Neuroimmunol. 2019. PMID: 30685069

8

High κ free light chain is a potential biomarker for double seronegative and ocular myasthenia gravis.

Wilf-Yarkoni A, Alkalay Y, Brenner T, Karni A. Wilf-Yarkoni A, et al. Among authors: karni a. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 14;7(5):e831. doi: 10.1212/NXI.0000000000000831. Print 2020 Sep. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32665296 Free PMC article.

9

Fingolimod Increases Brain-Derived Neurotrophic Factor Level Secretion from Circulating T Cells of Patients with Multiple Sclerosis.

Golan M, Mausner-Fainberg K, Ibrahim B, Benhamou M, Wilf-Yarkoni A, Kolb H, Regev K, Karni A. Golan M, et al. Among authors: karni a. CNS Drugs. 2019 Dec;33(12):1229-1237. doi: 10.1007/s40263-019-00675-7. CNS Drugs. 2019. PMID: 31713782

10

Vestibular function assessment of Susac syndrome patients by the video head impulse test and cervical vestibular-evoked myogenic potentials.

Oron Y, Handzel O, Habot-Wilner Z, Regev K, Karni A, Zur D, Baraquet D, Goldstein M, Elkayam O, Ungar OJ. Oron Y, et al. Among authors: karni a. J Vestib Res. 2020 Nov 4. doi: 10.3233/VES-200720. Online ahead of print. J Vestib Res. 2020. PMID: 33164965

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results